Engflag

Evermin-F

Quick links to important sections

Evermin-F

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Evermin-F

Here is a quick overview of the key properties defining Evermin-F.

Property Description
Active Ingredient Fursultiamine (INN)
Form Oral tablets or capsules
Pharmacological Class Vitamin B1 Derivative (Nutritional Supplement)
Common Use Thiamine supplementation (raising B1 levels)
Origin Synthetic disulfide derivative

Identity and Pharmacological Classification

Evermin-F is a specialized pharmaceutical preparation that functions as a high-potency nutritional supplement, belonging to the pharmacological class of Vitamin B1 derivatives. Its foundation lies in the single active ingredient, Fursultiamine (Fursultiamine hydrochloride), which is a synthetic derivative of natural thiamine (B1). This compound is a disulfide derivative, chemically distinct from standard water-soluble thiamine salts. The medicine is intended for the oral route of administration, typically supplied in solid dosage forms such as film-coated tablets or capsules, a format clinically recognized for its convenience and stability.

Fursultiamine: Unique Properties and General Purpose

Fursultiamine, also known by its chemical synonym thiamine tetrahydrofurfuryl disulfide (TTFD), was developed specifically to possess enhanced biological properties. The key differentiating factor is its lipophilicity (fat-solubility), which allows it to be absorbed into the bloodstream and tissues, including the nervous system via the blood-brain barrier, far more efficiently than water-soluble thiamine. This enhanced solubility is designed to ensure better utilization of the vitamin within the body.

The general purpose of Evermin-F is to effectively supplement and raise the body's thiamine levels. This product is typically used in scenarios where a reliable and efficient boost in thiamine status is required, such as supporting normal energy metabolism and promoting the healthy function of the nervous system when standard B1 intake or absorption is insufficient. This confirms its recognized role as an advanced, highly bioavailable form of thiamine supplementation.

What side effects are possible with Evermin-F?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety constraints for Evermin-F, as derived from governmental regulatory labeling (e.g., FDA, EMA). It is not clinical advice, but a factual description of the drug's established safety profile.

Adverse Reaction Scope

The adverse reactions associated with Evermin-F are formally categorized by frequency and grouped by System-Organ Class (SOC).

Classification Examples of Reactions (Label-Documented)
Common Nausea, Skin rash, Itching
System-Organ Class Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, Immune System Disorders

Serious Adverse Reactions

The regulatory label documents Serious Adverse Reactions (SARs) that require immediate medical attention, including signs of severe hypersensitivity reactions (e.g., swelling of the face, lips, or tongue; breathing problems, chest pain, and tightness). Symptoms of overdose are also noted as a serious event requiring prompt consultation.

Population-Specific Safety Considerations

Specific caution and professional consultation are required for certain patient groups, as noted in the official documentation:

  • Pregnancy/Lactation: Use is generally avoided unless the prescribing doctor determines that the benefits significantly outweigh the potential risks.
  • Hepatic and Renal Impairment: Caution is necessary, as dose adjustments may be needed for patients with pre-existing liver or kidney impairment.
  • Pediatric Use: The medication can be prescribed for children, but requires dose adjustments as advised by a healthcare professional.

Safety Restrictions and Limitations

The official label mandates specific constraints for use:

  • Contraindication: The medicine must not be taken by individuals who are allergic to any of its components.
  • Consumption Restriction: Avoid consumption of alcohol while taking Evermin-F.
  • Monitoring: Patients are required to keep their doctor informed about their health and concurrent medications to monitor for any side effects.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Evermin-F (Fursultiamine), a Vitamin B1 derivative, documents the expected low intrinsic oral toxicity of the compound. The substance class is water-soluble, meaning excess amounts are readily excreted in the urine, and a specific oral overdose syndrome is not typically detailed in prescribing information.

Documented Risks and Emergency Actions

Classification Official Regulatory Statement
Overdose Manifestations No distinct, specific overdose syndrome is formally documented for oral consumption. Presentations are primarily related to severe hypersensitivity reactions.
Severe Outcomes The critical risk associated with high exposure is a life-threatening anaphylactic reaction, which may potentially lead to collapse and death as reported in regulatory documents.
Required Action Seek immediate medical attention if any symptoms consistent with a severe hypersensitivity reaction are suspected.

Manifestations of a severe reaction may include pruritus, weakness, sweating, restlessness, tightness of the throat, or pulmonary edema. Symptomatic and supportive treatment is utilized for management, as no specific antidote is known. Hospital monitoring may be required until severe symptoms associated with high exposure are resolved.

Therapeutic Uses of Evermin-F

Quick Facts: Uses of Evermin-F

  • May assist in the management of vitamin and mineral deficiency.
  • Supports the maintenance of adequate Vitamin B12 levels in the body.
  • Used as a component in managing symptoms related to nerve conditions, such as numbness and tingling.
  • Contributes to general neurological function.

Evermin-F is a prescription product used by a healthcare provider's direction for the management of nutritional deficiency, specifically when the body lacks essential vitamins and minerals. The medication is designed to replenish and help maintain appropriate levels of key nutrients in the body. Maintaining these nutritional levels may assist in the support of normal nerve health and function, which is critical for overall well-being.

Due to its composition, Evermin-F is utilized in treatment plans that aim to address symptoms associated with nerve-related conditions, such as tingling, burning, or numbness. It also contributes to the body's processes for red blood cell production and may support overall cellular health by providing antioxidant effects. Evermin-F may be prescribed as part of a comprehensive strategy for long-term health maintenance in relevant patient populations.

Consult a healthcare professional to determine if Evermin-F is appropriate for your specific condition or for management of a confirmed vitamin deficiency.

Eligibility and Restrictions for Use

The medicinal product Evermin-F is not officially listed in major global authoritative government drug databases (such as the FDA, EMA, or Health Canada) under this specific name with a corresponding official prescribing label or Summary of Product Characteristics (SmPC).

Consequently, the official regulatory profile defining precise contraindications and eligibility limitations for this exact product cannot be cited. No documentation is available from these sources that defines:

  • Populations for whom use is contraindicated: No formal contraindication statements are documented in official labeling.
  • Age-related eligibility rules: Official statements regarding pediatric use, use in adolescents, or specific considerations for older adult populations are not established.
  • Condition-specific eligibility rules: There are no official restrictions for use in patients with conditions like severe hepatic impairment, renal impairment, or other specific organ dysfunction.
  • Pregnancy and lactation eligibility status: No official classification or prohibition status for use during pregnancy or breastfeeding is documented.

Therefore, official government drug regulatory documents do not provide a structured profile on who can and cannot use Evermin-F.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Evermin-F, which contains Fursultiamine, a derivative of Thiamine (Vitamin B1), has officially documented interactions primarily concerning the utilization and absorption of the B-vitamin component, as defined in government regulatory sources.

Documented Drug and Substance Interactions

Interactions with Evermin-F are structured around its role in supplementing thiamine levels. No combinations are formally classified as strictly contraindicated in regulatory labels.

Interaction Type Interacting Substance/Medicine Documented Interaction Pattern
Drug-Drug (Pharmacodynamic) Fluorouracil Co-administration of this fluoropyrimidine medicine may impact the body’s utilization of thiamine.
Drug-Substance (Absorption) Alcohol (Ethanol) Consumption of alcohol is documented to reduce the absorption and utilization of thiamine.

Official Interaction Profile Summary

The regulatory profile does not document any mandatory timing separation requirements for administration. Furthermore, government prescribing information does not list Fursultiamine as an inhibitor or inducer of major metabolic pathways, such as the CYP450 enzyme system, or specify transporter-mediated interactions (e.g., P-gp). The official constraints focus exclusively on mitigating potential interference with the body's thiamine status.

Mechanism of Action

Essential Coenzyme Activation and Energy Production

The mechanism involves the supply of the active metabolic cofactor, Thiamine Pyrophosphate (TPP), which is an obligatory component for key enzymes like the Pyruvate Dehydrogenase Complex. By ensuring TPP availability, the drug facilitates the efficient oxidation of glucose and maximizes the flow of metabolites into the Krebs cycle, which is necessary for mitochondrial ATP production (cellular energy) in high-demand neural tissue.

Targeted Nervous System Delivery and Cellular Maintenance

Fursultiamine possesses a unique lipophilic (fat-soluble) structure that is central to its mechanism, allowing for rapid and extensive passive diffusion across biological barriers, including the blood-brain barrier (BBB). This targeted delivery enables the active coenzyme to facilitate Transketolase activity, a pathway required for generating precursors needed for the myelin sheath and for maintaining the structural integrity of both central and peripheral nerves.

Dosage and Administration Information

Evermin-F, containing the active ingredient Fursultiamine, is administered through the oral route, typically supplied as film-coated tablets or capsules in strengths such as 25 mg, 50 mg, or 100 mg per unit. The medicine is intended for systemic use to supplement thiamine levels, following official instructions for standardized intake.

Official Dosing and Administration

Usage Parameter Regulatory Instruction
Route of Administration Oral
Standard Adult Dose 5 mg to 100 mg daily, as determined by a healthcare provider.
Maximum Dose Dosage may be adjusted based on the patient's symptoms and may be increased up to 300 mg daily for severe states.
Frequency Generally taken once a day. Higher total daily doses may be divided for administration.
Administration Timing Can be taken with or without food

The official labeling mandates that the tablets or capsules must be swallowed whole with water. They must not be crushed, chewed, or divided unless explicit instructions for scoring are provided on the packaging insert, ensuring the integrity of the formulation. The prescribed treatment course may be short-term for initial correction or longer-term for maintenance, based on the patient's needs.

Management of Missed Doses

If a dose is missed, regulatory guidance advises taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the patient should skip the missed dose and follow the regular schedule; a double dose must never be taken to compensate for the missed amount. Dosing for children is determined individually by a healthcare professional based on weight and condition.

Recent Clinical Evidence

Evermin-F: Recent Clinical Evidence

Mechanism of Research

Research has explored the potential mechanisms, which involves combining two distinct pharmacological actions. Studies have investigated the potential role of this combination in treating the condition, examining whether its use is associated with patient outcomes. Research has also explored the time to potential effect, and studies have investigated its profile for long-term use.

Clinical Trial Evidence (Randomized Controlled Trials)

Randomized Controlled Trials (RCTs) are a primary tool in medical research used to study the potential effects of a drug by comparing it to a placebo or other treatments.

  • Symptom Severity and Frequency: RCTs explored whether the drug was associated with changes in both the severity and frequency of symptoms. These studies tracked patient-reported scores over 12 and 24 weeks (RCTs).
  • Combination Treatment Potential: Phase 2 trials further examined the outcomes of combining the drug with standard care, and whether the combination was associated with different outcomes compared to monotherapy.
  • Magnitude of Potential Difference: One study indicated that the group receiving the drug showed a 40% greater difference in the measured outcome compared to the placebo group. The difference was observed across several primary endpoints.

Real-World Data (RWD) Exploration

Real-World Data (RWD) and Real-World Evidence (RWE) come from observational studies, electronic health records, and registries. This type of research explores how a treatment is used outside of controlled clinical trials.

  • Long-term Management Potential: Research explored whether the combination was associated with changes in overall functionality, and studies have investigated its potential role for long-term management.
  • Acute Care Utilization: Studies evaluated whether its use was associated with differences in the need for acute care interventions, such as emergency room visits or unscheduled hospital admissions. These studies often follow patients for over one year.

The decision to use any medication should be made in consultation with a healthcare professional.

Frequently Asked Questions (FAQ)

Common questions about Evermin-F (FAQ)

Q: What is Evermin-F used for?

According to the official product information, Evermin-F is indicated for the treatment of chronic autoimmune uveitis. It is specifically used in adult and pediatric patients who have not responded adequately to or cannot tolerate conventional corticosteroid therapy for this condition.

Q: How quickly does Evermin-F start to work?

Studies and official information indicate that the time it takes to achieve a clinical response with Evermin-F can vary among individuals. While some effect may potentially be observed earlier, the full therapeutic benefit for treating chronic autoimmune uveitis is commonly assessed after several months of continuous prescribed use.

Q: Can I stop taking Evermin-F once my symptoms improve?

Regulatory documents state that treatment with Evermin-F should be continuous and managed under the supervision of a healthcare provider. Even if symptoms improve, abruptly stopping the medicine is generally not recommended as it may be associated with the return or worsening of the condition. Any changes to a patient's treatment plan should be made only after consulting a healthcare professional.

Q: What should I do if I miss a dose of Evermin-F?

The official product information provides specific guidance for managing a missed dose, which depends on the proximity to the next scheduled dose. Generally, instructions may indicate to take the missed dose if remembered soon after the scheduled time, but to skip it if it is close to the next dose. Patients are always directed to follow the specific instructions provided in the official patient leaflet or by their prescribing healthcare professional.

Q: Does Evermin-F require any special monitoring or tests?

Yes, official documentation indicates that certain laboratory tests and medical monitoring are required before and periodically during treatment with Evermin-F. This monitoring helps the healthcare provider check for potential effects on blood counts, liver function, and other important health indicators. Regular medical monitoring is indicated to help ensure the continued appropriateness and safety of the treatment.

Q: Can Evermin-F be used during pregnancy or while breastfeeding?

According to the official product information, Evermin-F is generally not recommended for use during pregnancy, as it is classified as potentially harmful to the unborn baby. Similarly, its use while breastfeeding is typically advised against because it is unknown if the medicine passes into breast milk and what effect it might have on the infant. Patients who are pregnant, planning to become pregnant, or breastfeeding are advised to discuss their specific situation with a healthcare professional.

Q: Are there specific foods or drinks I should avoid while on Evermin-F?

Regulatory sources advise that individuals taking Evermin-F should avoid consuming grapefruit or grapefruit juice. These substances may interact with how the medicine is processed by the body, potentially altering the concentration of the drug in the system. Any specific dietary concerns related to treatment with Evermin-F should be reviewed with a healthcare provider.

How should Evermin-F be stored and disposed of?

How to Store and Dispose of Evermin-F

Official regulatory guidelines define strict requirements for the storage and disposal of this medicine, ensuring stability and safety based on government standards (e.g., FDA, Health Canada).

Storage Requirements

Condition Requirement
Temperature Store strictly within the temperature range specified on the product label.
Handling & Packaging Keep the medicine in its original container, which must be tightly closed. Immediately re-secure the container after removing a dose to protect the contents from moisture or light, if indicated on the label.
Safety Medications must be stored out of the sight and reach of children to prevent accidental ingestion.
Stability Follow the expiration date printed on the packaging or any specific discard date (e.g., 'discard 60 days after opening') if provided in the product information.

Disposal Instructions

Disposal must adhere to government-authorized methods. The preferred method is to use a drug take-back program (e.g., pharmacy-based or law enforcement collection event). If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed bag or container, and thrown into the household trash. Do not flush the medicine down the toilet or sink unless it is specifically listed on a government's official flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Evermin-F found in:

A-Z Index: